Straits Times Index
3,343.94 +5.00 (+0.15%) Nikkei
38,527.60 -309.86 (-0.80%) Hang Seng
18,512.82 +68.71 (+0.37%) FTSE 100
8,232.04 -30.71 (-0.37%) Bitcoin USD
70,819.84 +1,610.24 (+2.33%) CMC Crypto 200
1,477.70 +30.55 (+2.11%)
PFE Jun 2024 24.000 call
| Previous close | 3.5100 |
| Open | 3.5100 |
| Bid | 3.8500 |
| Ask | 6.6500 |
| Strike | 24.00 |
| Expiry date | 2024-06-14 |
| Day's range | 3.5100 - 3.5100 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
BenzingaPromising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial. On Monday, Moderna (NASDAQ: MRNA) and Merck & Co (NYSE: MRK) also reported durable efficiency of their combined melanoma treatment that consists of an experimental mRNA vaccine and Merck’s blockbuster immunotherapy, Keytruda. Pfizer Is Aiming To Set The Treatment Standard For Lung Cancer With encouraging results, Pfizer is getting another step closer t
ZacksFDA Panel to Consider Updating COVID-19 Jabs for New Virus Strains
An FDA panel meeting is scheduled on Jun 5 to consider if COVID-19 vaccines should be updated to target the WHO-recommended JN.1 variant or the KP.2 variant which is the currently dominating strain in the country.
Insider MonkeyIs Pfizer Inc. (NYSE:PFE) the Best Gene Therapy Stock to Buy Now?
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Pfizer Inc. (NYSE:PFE) is the best gene therapy stock to buy now. Gene therapy involves treating illnesses by modifying, replacing, or supplementing faulty or missing genes responsible for a disease. This approach has […]
